Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

 Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018

Shots:

  • The two P-III trials SUNBEAM (N=1346) and RADIANCE (N=1320) involves assessing of two doses of ozanimod PO (0.92 & 0.46 mg, equivalent to 1 & 0.5 mg ozanimod HCI) vs 1L Avonex in RMS patients for @12 mos. & @24 mos. respectively
  • P-III SUNBEAM & RADIANCE Part B results: early & advance RMS (1 &0.5mg vs IFN): ARR@12mos. (0.149,0.217; 0.200, 0.277 vs 0.285,0.363); mean number of gadolinium-enhancing(GdE) (0.263, 0.278; 0.458, 0.32 vs 0.656, 0.915); mean number of new or enlarging T2 lesions (2.952, 2.514; 3.744, 2.903 vs 4.633, 4.710)
  • Ozanimod is PO sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5) receptor modulator indicated to treat RMS, UC and Crohn’s disease. Avonex (IFN) is a interferon beta-1a used to treat MS

Click here to read full press release/ article | Ref: Celgene | Image Fierce Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post